scispace - formally typeset
Open AccessJournal ArticleDOI

Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy

TLDR
The screening goal was to establish structure-activity relationships (SAR) for the different chemical series to identify the molecular composition that most efficiently led to tau degradation in human FTD ex vivo neurons, and the identification of the lead compound QC-01-175 and follow-up optimization strategies for this molecule are described.
Abstract
Accumulation of misfolded, aggregating proteins concurrent with disease onset and progression is a hallmark of neurodegenerative proteinopathies. An important class of these are tauopathies, such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD), associated with accumulation of aberrant forms of tau protein in the brain. Pathological tau undergoes abnormal post-translational modifications, misfolding, oligomerization and changes in solubility, cellular redistribution, and spreading. Development and testing of experimental therapeutics that target these pathological tau conformers requires use of cellular models that recapitulate neuronal endogenous, non-heterologous tau expression under genomic and physiological contexts relevant to disease. In this study, we employed FTD-patient induced pluripotent stem cells (iPSC)-derived neurons, expressing a tau variant or mutation, as primary models for driving a medicinal chemistry campaign around tau targeting degrader series. Our screening goal was to establish structure-activity relationships (SAR) for the different chemical series to identify the molecular composition that most efficiently led to tau degradation in human FTD ex vivo neurons. We describe the identification of the lead compound QC-01-175 and follow-up optimization strategies for this molecule. We present three final lead molecules with tau degradation activity in mutant neurons, which establishes potential disease relevance and will drive future studies on specificity and pharmacological properties.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.

TL;DR: In this paper , small molecule-based PhosTACs were used to recruit tau to PP2A, a native tau phosphatase, and induced the formation of a stable ternary complex, leading to rapid, efficient, and sustained tau dephosphorylation.
Journal ArticleDOI

Conserved gene signatures shared among MAPT mutations reveal defects in calcium signaling

TL;DR: It is demonstrated that iPSC-derived neurons capture molecular processes that occur in human brains and can be used to pinpoint common molecular pathways involving synaptic and endolysosomal function and neuronal development, which may be regulated by disruptions in calcium homeostasis.
Journal ArticleDOI

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase

TL;DR: In this paper , a series of c-Met-targeting cabozantinib-based PROTACs were developed, bearing a VHL-ligand as an E3-ligase binding moiety and glycol-based linkers.
Journal ArticleDOI

Involvement of heterologous ubiquitination including linear ubiquitination in Alzheimer’s disease and amyotrophic lateral sclerosis

TL;DR: In this article , the linear ubiquitin chain assembly complex (LUBAC)-mediated Met1-linked linear UCLU chain, which activates the canonical NF-κB pathway, is also involved in cytoplasmic inclusions of tau in AD and TAR DNA-binding protein 43 in ALS.
Journal ArticleDOI

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma

TL;DR: In this article , the effects and mechanisms underlying the drug-to-drug interactions between IMiDs and peroxisome proliferator-activated receptor (PPAR) agonists in multiple myeloma (MM) were analyzed.
References
More filters
Journal ArticleDOI

CellProfiler: image analysis software for identifying and quantifying cell phenotypes

TL;DR: The first free, open-source system designed for flexible, high-throughput cell image analysis, CellProfiler is described, which can address a variety of biological questions quantitatively.
Journal ArticleDOI

Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

TL;DR: In this paper, the authors sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon in
Journal ArticleDOI

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

TL;DR: The data suggest that tauopathy associated with sporadic Alzheimer disease may begin earlier than previously thought and possibly in the lower brainstem rather than in the transentorhinal region.
Journal ArticleDOI

Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy

TL;DR: The data suggest that even brief elevations in Aβ production, may have enduring impact on the risk for tauopathy, and Soluble Aβ1-42 oligomers have long-lasting effects on tau phosphorylation in the rTg4510 model.
Journal ArticleDOI

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

TL;DR: Using quantitative proteomics, it is found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKzF3, by the CRBN-CRL4 ubiquitin ligase, which are essential transcription factors in multiple myeloma.
Related Papers (5)
Trending Questions (1)
Can iPSC lower tau protein in AD?

The paper does not directly address the question of whether iPSC can lower tau protein in Alzheimer's disease (AD). The paper focuses on the use of FTD-patient induced pluripotent stem cells (iPSC)-derived neurons to drive a medicinal chemistry campaign around tau targeting degrader series.